Although perturbations in RUNX1T1 expression produced no obvious phenotypic changes in our study, recent discoveries in GEMMs show that multiple epigenetic modifiers (NFIB, EZH2, and CREBBP/EP300) are involved in SCLC development and progression [33, 34, 35, 36]. This evidence concerns the gene EZH2 and small cell lung carcinoma.